Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Current Deferred Revenue (2019 - 2025)

Historic Current Deferred Revenue for Vivos Therapeutics (VVOS) over the last 7 years, with Q3 2025 value amounting to $538000.0.

  • Vivos Therapeutics' Current Deferred Revenue fell 6391.68% to $538000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $538000.0, marking a year-over-year decrease of 6391.68%. This contributed to the annual value of $993000.0 for FY2024, which is 5908.53% down from last year.
  • Latest data reveals that Vivos Therapeutics reported Current Deferred Revenue of $538000.0 as of Q3 2025, which was down 6391.68% from $485000.0 recorded in Q2 2025.
  • Vivos Therapeutics' Current Deferred Revenue's 5-year high stood at $4.1 million during Q2 2021, with a 5-year trough of $485000.0 in Q2 2025.
  • For the 5-year period, Vivos Therapeutics' Current Deferred Revenue averaged around $2.3 million, with its median value being $2.4 million (2023).
  • Per our database at Business Quant, Vivos Therapeutics' Current Deferred Revenue surged by 3405.83% in 2023 and then crashed by 7973.39% in 2025.
  • Quarter analysis of 5 years shows Vivos Therapeutics' Current Deferred Revenue stood at $2.4 million in 2021, then grew by 26.64% to $3.0 million in 2022, then dropped by 20.11% to $2.4 million in 2023, then crashed by 59.09% to $993000.0 in 2024, then crashed by 45.82% to $538000.0 in 2025.
  • Its Current Deferred Revenue stands at $538000.0 for Q3 2025, versus $485000.0 for Q2 2025 and $594000.0 for Q1 2025.